The Fabry Disease Market to Grow Positively at a Paltry CAGR of 7.65% During the Study Period (2019–2032), Assesses DelveInsight

Published February 1, 2023

Nevada (Las Vegas), United States, DelveInsight’s “Fabry Disease – Market Insight, Epidemiology and Market Forecast – 2032” report provides current treatment practices, emerging drugs, Fabry Disease market share of the individual therapies, current and forecasted Fabry Disease market size from 2019 to 2032 segmented by seven major markets. The report also offers current Fabry Disease therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Fabry Disease market.

Fabry Disease Overview
Fabry disease is an inherited lysosomal storage disorder caused by alpha-galactosidase A, a nonfunctional or partially functional enzyme (-Gal A). Reduced -Gal A activity in lysosomes causes an accumulation of enzyme substrates (Gb3 and lyso-Gb3), causing cellular damage throughout the body.
Despite being X-linked, heterozygous women may experience all of the signs and symptoms seen in men; however, when compared to hemizygous males, Fabry disease signs and symptoms in women typically appear later and with less severity.

Fabry disease symptoms include widespread pain (referred to as a Fabry crisis), gastrointestinal complications, headaches, decreased sweating, vertigo, and hearing loss. Fabry disease is diagnosed using a variety of tests, including enzyme assays and newborn screening.

Fabry Disease Epidemiological Insights
As per the assessment done by DelveInsight, the total Fabry disease prevalent cases in the seven major markets was reported to be 13K in 2021.

Among the EU5 countries, Germany had the highest number of Fabry disease prevalent cases in 2021.

Fabry Disease Treatment Market
Enzyme replacement therapy (ERT), oral chaperone therapy, and adjunctive treatment such as ACE inhibitors or angiotensin receptor blockers, antiplatelet drugs, and analgesics are used to treat Fabry disease. ERT has been shown in studies to postpone, but not always prevent, some clinical complications of FD. At the moment, effective Fabry disease management requires a multidisciplinary approach that includes intravenous ERT or chaperone therapy, as well as adjunct therapies such as lifestyle changes and prophylactic medications.
In the United States, there are currently only two therapies approved for the treatment of Fabry disease: Galafold (Amicus Therapeutics) and Fabrazyme (Sanofi-Genzyme). Replagal (Takeda/Shire), Fabrazyme (Sanofi-Genzyme), and Galafold (Amicus Therapeutics) are the only approved therapies for Fabry disease patients in the European and Japanese markets.

Promising Therapies in the Fabry Disease Pipeline
• PRX-102 (Pegunigalsidase Alfa)
• Venglustat
• ST-920
• FLT190
• 4D-310
• Lucerastat
• Moss-aGal

Discover more about Fabry Disease therapies in the pipeline @ Fabry Disease Drugs

Leading Companies Working in the Fabry Disease Market
• Protalix Biotherapeutics
• Sanofi Genzyme
• Sangamo Therapeutics
• Freeline Therapeutics
• 4D Molecular Therapeutics
• Idorsia Pharmaceuticals
• Shire
• Takeda
• Amicus Therapeutics
• Protalix
• uniQure
• Codexis
• MP6 Therapeutics
• CellGenTech

Learn more about the recent developments and breakthroughs in the Fabry Disease market @ Fabry Disease Clinical Trials

Fabry Disease Market Dynamics
Several companies are working hard to develop new therapies with novel mechanisms of action to address the current unmet needs of the Fabry disease market and to provide better treatment options. Furthermore, numerous therapies are being studied in various stages of clinical trials. These include pegylated forms of -GAL, gene therapy, and substrate reduction therapy.

As per DelveInsight analysis, the Fabry disease market size in the 7MM was approximately USD 1,200 million in 2021.

Certain factors, however, are influencing the growth of the Fabry disease market. Enzyme and chaperone therapies are expensive and invasive, requiring biweekly infusions, slowing the growth of the Fabry disease market. Furthermore, gene therapy is costly; additionally, most countries, including the United States healthcare systems, are not designed to handle large one-time payments.

Scope of the Fabry Disease Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, Japan]
Key Fabry Disease Companies: Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, GREENOVATION BIOTECH GMBH, Shire, Takeda, Amicus Therapeutics, Protalix, uniQure, Codexis, MP6 Therapeutics, CellGenTech, and others
Key Fabry Disease Pipeline Therapies: PRX-102 (Pegunigalsidase Alfa), Venglustat, ST-920, FLT190, 4D-310, Lucerastat, Moss-aGal, and others
Therapeutic Assessment: Fabry Disease current marketed and emerging therapies
Fabry Disease Market Dynamics: Fabry Disease market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Fabry Disease Market Access and Reimbursement

Table of Contents
1. Fabry Disease Market Key Insights
2. Fabry Disease Market Report Introduction
3. Fabry Disease Market Overview at a Glance
4. Fabry Disease Market Executive Summary
5. Disease Background and Overview
6. Fabry Disease Treatment and Management
7. Fabry Disease Epidemiology and Patient Population
8. Patient Journey
9. Fabry Disease Emerging Drugs
10. 7MM Fabry Disease Market Analysis
11. Fabry Disease Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Fabry Disease Market Drivers
15. Fabry Disease Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Sandeep Joshi